Literature DB >> 27705091

Guillain-Barré Syndrome Associated with Zika Virus Infection in Colombia.

Beatriz Parra1, Jairo Lizarazo1, Jorge A Jiménez-Arango1, Andrés F Zea-Vera1, Guillermo González-Manrique1, José Vargas1, Jorge A Angarita1, Gonzalo Zuñiga1, Reydmar Lopez-Gonzalez1, Cindy L Beltran1, Karen H Rizcala1, Maria T Morales1, Oscar Pacheco1, Martha L Ospina1, Anupama Kumar1, David R Cornblath1, Laura S Muñoz1, Lyda Osorio1, Paula Barreras1, Carlos A Pardo1.   

Abstract

BACKGROUND: Zika virus (ZIKV) infection has been linked to the Guillain-Barré syndrome. From November 2015 through March 2016, clusters of cases of the Guillain-Barré syndrome were observed during the outbreak of ZIKV infection in Colombia. We characterized the clinical features of cases of Guillain-Barré syndrome in the context of this ZIKV infection outbreak and investigated their relationship with ZIKV infection.
METHODS: A total of 68 patients with the Guillain-Barré syndrome at six Colombian hospitals were evaluated clinically, and virologic studies were completed for 42 of the patients. We performed reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assays for ZIKV in blood, cerebrospinal fluid, and urine, as well as antiflavivirus antibody assays.
RESULTS: A total of 66 patients (97%) had symptoms compatible with ZIKV infection before the onset of the Guillain-Barré syndrome. The median period between the onset of symptoms of ZIKV infection and symptoms of the Guillain-Barré syndrome was 7 days (interquartile range, 3 to 10). Among the 68 patients with the Guillain-Barré syndrome, 50% were found to have bilateral facial paralysis on examination. Among 46 patients in whom nerve-conduction studies and electromyography were performed, the results in 36 patients (78%) were consistent with the acute inflammatory demyelinating polyneuropathy subtype of the Guillain-Barré syndrome. Among the 42 patients who had samples tested for ZIKV by RT-PCR, the results were positive in 17 patients (40%). Most of the positive RT-PCR results were in urine samples (in 16 of the 17 patients with positive RT-PCR results), although 3 samples of cerebrospinal fluid were also positive. In 18 of 42 patients (43%) with the Guillain-Barré syndrome who underwent laboratory testing, the presence of ZIKV infection was supported by clinical and immunologic findings. In 20 of these 42 patients (48%), the Guillain-Barré syndrome had a parainfectious onset. All patients tested were negative for dengue virus infection as assessed by RT-PCR.
CONCLUSIONS: The evidence of ZIKV infection documented by RT-PCR among patients with the Guillain-Barré syndrome during the outbreak of ZIKV infection in Colombia lends support to the role of the infection in the development of the Guillain-Barré syndrome. (Funded by the Bart McLean Fund for Neuroimmunology Research and others.).

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27705091     DOI: 10.1056/NEJMoa1605564

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  188 in total

1.  Antibody-based assay discriminates Zika virus infection from other flaviviruses.

Authors:  Angel Balmaseda; Karin Stettler; Raquel Medialdea-Carrera; Damaris Collado; Xia Jin; José Victor Zambrana; Stefano Jaconi; Elisabetta Cameroni; Saira Saborio; Francesca Rovida; Elena Percivalle; Samreen Ijaz; Steve Dicks; Ines Ushiro-Lumb; Luisa Barzon; Patricia Siqueira; David W G Brown; Fausto Baldanti; Richard Tedder; Maria Zambon; A M Bispo de Filippis; Eva Harris; Davide Corti
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-17       Impact factor: 11.205

2.  Implementation and Evaluation of Guillain-Barré Syndrome Surveillance in Puerto Rico during the 2016 Zika Virus Epidemic.

Authors:  Chelsea G Major; Emilio Dirlikov; Nicole A Medina; Roberta Lugo-Robles; Desiree Matos; Jorge Muñoz-Jordán; Candimar Colón-Sánchez; Myriam García-Negrón; Marangely Olivero-Segarra; Graciela Malavé-González; Dana L Thomas; Carlos A Luciano; Stephen H Waterman; James Sejvar; Tyler M Sharp; Brenda Rivera-García
Journal:  P R Health Sci J       Date:  2018-12       Impact factor: 0.705

3.  Clinical Features of Guillain-Barré Syndrome With vs Without Zika Virus Infection, Puerto Rico, 2016.

Authors:  Emilio Dirlikov; Chelsea G Major; Nicole A Medina; Roberta Lugo-Robles; Desiree Matos; Jorge L Muñoz-Jordan; Candimar Colon-Sanchez; Myriam Garcia; Marangely Olivero-Segarra; Graciela Malave; Gloria M Rodríguez-Vega; Dana L Thomas; Stephen H Waterman; James J Sejvar; Carlos A Luciano; Tyler M Sharp; Brenda Rivera-García
Journal:  JAMA Neurol       Date:  2018-09-01       Impact factor: 18.302

Review 4.  CNS Infections in 2016: 2016, the year of Zika virus.

Authors:  Diederik van de Beek; Matthijs C Brouwer
Journal:  Nat Rev Neurol       Date:  2017-01-13       Impact factor: 42.937

Review 5.  Guillain-Barré syndrome: a century of progress.

Authors:  John A Goodfellow; Hugh J Willison
Journal:  Nat Rev Neurol       Date:  2016-11-18       Impact factor: 42.937

6.  Zika virus induced cellular remodelling.

Authors:  Evan D Rossignol; Kristen N Peters; John H Connor; Esther Bullitt
Journal:  Cell Microbiol       Date:  2017-04-18       Impact factor: 3.715

7.  Outer Membrane Vesicles from Neisseria Meningitidis (Proteossome) Used for Nanostructured Zika Virus Vaccine Production.

Authors:  Paula Martins; Daisy Machado; Thais Holtz Theizen; João Paulo Oliveira Guarnieri; Bruno Gaia Bernardes; Gabriel Piccirillo Gomide; Marcus Alexandre Finzi Corat; Camilla Abbehausen; José Luiz Proença Módena; Carlos Fernando Odir Rodrigues Melo; Karen Noda Morishita; Rodrigo Ramos Catharino; Clarice Weis Arns; Marcelo Lancellotti
Journal:  Sci Rep       Date:  2018-05-29       Impact factor: 4.379

Review 8.  Taking the defensive: Immune control of Zika virus infection.

Authors:  James R Bowen; Matthew G Zimmerman; Mehul S Suthar
Journal:  Virus Res       Date:  2017-09-01       Impact factor: 3.303

Review 9.  Zika virus vaccines: immune response, current status, and future challenges.

Authors:  Justin M Richner; Michael S Diamond
Journal:  Curr Opin Immunol       Date:  2018-05-10       Impact factor: 7.486

Review 10.  Vaccination strategies against Zika virus.

Authors:  Estefania Fernandez; Michael S Diamond
Journal:  Curr Opin Virol       Date:  2017-04-19       Impact factor: 7.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.